13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q2 2025 · Filed August 14, 2025 · Accession 0000950123-25-008066
Total Value
$154.4M
Positions
13
Other Managers
0
Confidential Omitted
No
Holdings (13)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Beta Bionics Inc. | BBNX | 1,988,287 | $28.9M | 18.75% |
| 2 | Kestra Med Technologies Ltd. | BEKE | 1,645,893 | $27.3M | 17.67% |
| 3 | Upstream Bio Inc. | UPB | 2,036,293 | $22.4M | 14.48% |
| 4 | Nuvation Bio | NUVB | 11,042,728 | $21.5M | 13.94% |
| 5 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $20.5M | 13.26% |
| 6 | Replimune Group | REPL | 1,975,203 | $18.3M | 11.88% |
| 7 | Lexeo Therapeutics | LXEO | 1,184,636 | $4.8M | 3.08% |
| 8 | Ikena Oncology | 45175G108 | 2,249,123 | $3.0M | 1.95% |
| 9 | Sana Biotechnology, Inc. | SANA | 843,750 | $2.3M | 1.49% |
| 10 | Alumis Inc. | ALMS | 653,223 | $2.0M | 1.27% |
| 11 | enGene Holdings Inc. | ENGNW | 526,357 | $1.9M | 1.24% |
| 12 | Immunic Inc. | IMUX | 1,788,160 | $1.2M | 0.81% |
| 13 | enGene Holdings Inc. | ENGNW | 321,502 | $272,955 | 0.18% |